Table 1 Study characteristics of included studies (n = 119)
Characteristic | n | % |
|---|---|---|
Study type | Â | Â |
Development only | 100 | 84.0% |
Development with external validation | 19 | 16.0% |
Data source | Â | Â |
Existing data | 75 | 63.0% |
Prospectively collected cohort | 23 | 19.3% |
Registry data | 11 | 9.2% |
Case control study | 5 | 4.2% |
Cross-sectional | 4 | 3.4% |
Randomised controlled trial | 1 | 0.8% |
Clinical specialty | Â | Â |
Oncology | 20 | 16.8% |
Cardiovascular related | 19 | 16.0% |
Gastroenterology and hepatology | 13 | 10.9% |
Infectious diseases | 9 | 7.6% |
Neurology | 9 | 7.6% |
Obstetrics and gynaecology | 9 | 7.6% |
Endocrinology and metabolic disorders | 5 | 4.2% |
Respiratory disorder | 5 | 4.2% |
Trauma and Orthopaedics | 5 | 4.2% |
Intensive Care Unit | 4 | 3.4% |
Radiology | 3 | 2.5% |
General population | 3 | 2.5% |
Urology | 3 | 2.5% |
Haematology | 3 | 2.5% |
Surgical patients | 2 | 1.7% |
Rheumatology | 1 | 0.8% |
Geriatric medicine | 1 | 0.8% |
Paediatrics | 1 | 0.8% |
Emergency medicine | 1 | 0.8% |
Ophthalmology | 1 | 0.8% |
Psychiatry | 1 | 0.8% |
Not specified | 1 | 0.8% |
Prediction type | Â | Â |
Prognostic | 88 | 73.9% |
Health event* | 30 | 34.1% |
Mortality | 19 | 21.6% |
Complication | 16 | 18.2% |
Health status** | 14 | 15.9% |
Treatment related | 8 | 9.1% |
Readmission | 1 | 1.1% |
Diagnostic | 31 | 26.1% |
Disease presence | 31 | 100.0% |